Delivery Order SPE2DB25D3006-SPE2DB25FXKBH
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,500.82 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens on July 30, 2025. This firm fixed-price delivery order, which represents a non-set-aside competitive award, is scheduled for completion by July 31, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract involves the supply of a diabetes and weight management...
- The Defense Logistics Agency awarded a delivery order valued at $11,057.47 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 ml pen injections on August 8, 2025. This firm fixed-price delivery order, with a completion date of August 11, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location in...
- The Defense Logistics Agency awarded a $16,652.51 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 31, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase requisition under...
- The Defense Logistics Agency awarded a $14,089.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. The award was competitively procured with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $7,993.05 firm fixed price delivery order to AmerisourceBergen Drug Corp for ZEPBOUND (tirzepatide) 5 mg/0.5 ml pen injections on August 18, 2025, with an ultimate completion date of August 19, 2025. This non-competitive delivery order represents a single-use purchase of the FDA-approved diabetes and weight management medication under the company's existing contract vehicle. The performance location is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,538.13 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens on August 4, 2025. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 5, 2025, and represents a direct pharmaceutical procurement to support federal healthcare needs. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,939.78 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pens on July 28, 2025, with completion scheduled for July 29, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and represents a small-value transaction within AmerisourceBergen's broader pharmaceutical supply portfolio. The product will be delivered to the company's location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $21,523.36 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 12.5 mg/0.5 mL pen injections. The contract, awarded on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a firm fixed price delivery order with no set-aside designation. Performance will be executed from AmerisourceBergen's Conshohocken, Pennsylvania facility, which serves as the company's corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (tirzepatide) 2.5 mg/0.5 ml pen injectors in 0.5 ml quantities. This firm fixed-price delivery order, valued at $9,394.59, represents a competitive award with no set-aside designation and is set for completion by August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, serving the federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $14,950.78 to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of Zepbound (tirzepatide) 15 mg/0.5 mL pen injectors. This competitively awarded, firm fixed-price contract is scheduled for completion by July 24, 2025, with performance taking place at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. The contract represents a single delivery order issued under a larger procurement vehicle and carries...
- SPE2DB25D3006Indefinite Delivery Contract
- SPE2DB25D3006-SPE2DB25FXKBHDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $8,913.29 to AmerisourceBergen Drug Corp for Zepbound (tirzepatide) 10 mg/0.5 mL pens on August 12, 2025, with completion targeted for August 13, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to supply the injectable diabetes medication to support federal healthcare requirements. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is the awardee, with the place of performance also located in Conshohocken. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The IDC serves as a comprehensive global pharmaceutical supply vehicle enabling AmerisourceBergen to deliver a broad range of medications and medical supplies to support military healthcare programs worldwide. The company's federal contract portfolio demonstrates extensive experience fulfilling medical procurement needs for the Defense Health Agency and other government healthcare systems through competitively awarded orders covering diverse pharmaceutical products including specialty medications, vaccines, and medical devices across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 8/12/25 |